

PATENT

Case Docket No. TRIPEP.007CP3C1

Date: September 16, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Matti Sallberg
Appl. No. : 10/608,541
Filed : June 27, 2003
For : LIGAND/RECEPTOR
SPECIFICITY EXCHANGERS
THAT REDIRECT
ANTIBODIES TO RECEPTORS
ON A PATHOGEN
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 16, 2003

(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with one hundred fifty-six (156) references listed, fifty (50) of which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Matti Sallberg
App. No. : 10/608,541
Filed : June 27, 2003
For : LIGAND/RECEPTOR SPECIFICITY
EXCHANGERS THAT REDIRECT
ANTIBODIES TO RECEPTORS ON A
PATHOGEN
Examiner : Unknown
Group Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing one hundred fifty-six (156) references, fifty (50) of which are enclosed. One hundred six (106) of the listed references, which are not enclosed, were cited and submitted in related application no. 09/664945 filed September 19, 2000, which priority is relied upon under 35 U.S.C. § 120. No copies of the references are required under 37 C.F.R. § 1.98(d) for these one hundred six (106) references.

This Information Disclosure Statement is being filed within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9/16/2003

By: 

Eric S. Furman, Ph.D.
Registration No. 49,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.007CP3C1APPLICATION NO.
10/608,541INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Matti SällbergFILING DATE
June 27, 2003GROUP
Unknown

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,169,138	09/25/79	Jonsson		
	2	4,376,110	03/08/83	David et al.		
	3	4,471,058	09/11/84	Smith et al.		
	4	4,486,530	12/04/84	David et al.		
	5	4,589,881	05/20/85	Pierschbacher et al.		
	6	4,946,778	08/07/90	Ladner et al.		
	7	5,091,513	02/25/92	Huston et al.		
	8	5,175,096	12/29/92	Hook et al.		
	9	5,189,015	02/23/93	Hook et al.		
	10	5,196,510	03/23/93	Rodwell et al.		
	11	5,260,189	11/09/93	Formoso et al.		
	12	5,320,951	06/14/94	Hook et al.		
	13	5,416,021	05/16/95	Hook et al.		
	14	5,440,014	08/08/95	Hook et al.		
	15	5,561,049	10/10/96	Vold et al.		
	16	5,571,511	11/05/96	Fischer		
	17	5,571,514	11/05/96	Hook et al.		
	18	5,582,975	12/10/96	Milliman		
	19	5,601,830	02/11/97	Su et al.		
	20	5,627,263	05/06/97	Ruoslahti et al.		
	21	5,652,217	07/29/97	Hook et al.		
	22	5,700,928	12/23/97	Hodgson et al.		
	23	5,766,951	06/16/98	Brown		
	24	5,766,857	06/16/98	Ruoslahti et al.		
	25	5,770,208	06/23/98	Fattom et al.		
	26	5,770,702	06/23/98	Hook et al.		
	27	5,776,712	07/07/98	Kuusela et a.		
	28	5,789,549	08/04/98	Hook et al.		
	29	5,840,846	11/24/98	Hook et al.		
	30	5,843,774	12/01/98	Ginsberg		

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.007CP3C1	APPLICATION NO. 10/608,541
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Matti Sällberg	
		FILING DATE June 27, 2003	GROUP Unknown




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	31	5,846,536	12/08/98	Bissell et al.			
	32	5,866,541	02/02/99	Hook et al.			
	33	5,869,232	02/09/99	Sällberg			
	34	5,888,738	03/30/99	Hendry			
	35	5,929,220	07/27/99	Tong et al.			
	36	5,942,606	08/24/99	Lal et al.			
	37	5,955,078	09/21/99	Burnham et al.			
	38	5,980,908	11/09/99	Hook et al.			
	39	5,981,274	11/09/99	Tyrell et al.			
	40	6,008,341	12/28/99	Foster et al.			
	41	6,030,613	02/29/00	Blumberg et al.			
	42	6,040,137	03/21/00	Sällberg			
	43	6,066,648	05/23/00	Duggan et al.			
	44	6,077,677	06/01/00	Hodgson et al			
	45	6,086,875	07/11/00	Blumberg et al.			
	46	6,086,895	07/11/00	Hook et al.			
	47	6,087,330	07/11/00	Kogan et al.			
	48	6,090,388	07/18/00	Wang			
	49	6,090,944	07/18/00	Hutchinson			
	50	6,093,539	06/25/00	Moddon et al.			
	51	6,245,985	06/12/01	Sällberg			
	52	6,417,324	07/09/02	Sällberg			
	53	6,485,726B1	11/26/02	Blumberg et al.			
	54	2002/0025513 A1	02/28/02	Sällberg			
	55	2002/0058247 A1	05/16/02	Sällberg			
	56	2003/0021789A1	01/30/03	Xu et al.			
	57	2003/0044418A1	03/06/03	Davis et al.			


FOREIGN PATENT DOCUMENTS

EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
EXAMINER				DATE CONSIDERED			
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.							

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.007CP3C1	APPLICATION NO. 10/608,541
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) 		APPLICANT Matti Sällberg	
		FILING DATE June 27, 2003	GROUP Unknown

INITIAL							YES	NO
	58	0 182 546 A2	05/28/86	EP				
	59	0 508 427 A	10/14/92	EP				
	60	WO 93/15210	08/05/93	WIPO				
	61	WO 93/17044	09/02/93	WIPO				
	62	WO 94/13804	06/23/94	WIPO				
	63	WO 95/08577	03/30/95	WIPO				
	64	WO 95/22249 A	05/11/00	PCT				
	65	WO 95/29938	11/09/95	WIPO				
	66	WO 98/03543	01/29/98	WIPO				
	67	WO 98/31389	07/23/98	WIPO				
	68	WO 99/27109	06/03/99	WIPO				
	69	WO 99/61041 A	12/02/99	PCT				
	70	WO 00/26385 A	05/11/00	PCT				
	71	WO 00/66621	11/09/00	WIPO				
	72	WO 01/81421	11/01/01	WIPO				
	73	WO 02/24887	03/28/02	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	74	Barbas et al., "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site," <i>Proc Natl Acad Sci USA</i> , 88:7978-7982, (1991).
	75	Bianchi et al., "Chemical Synthesis of a Designed Beta-Protein through the Flow-Polyamide Method," <i>Int J Pept Protein Res</i> , 41(4):385-393 (1993).
	76	Bianchi et al., "Afinity Purification of a Difficult-Sequence Protein: Implications for the Inclusion of Capping in Synthetic Protocols," <i>Int J Pept Protein Res</i> , 42(1):93-96 (1993).
	77	Bichko et al., "Epitopes recognized by antibodies to denatured core protein of hepatitis B virus," <i>Mol. Immunol.</i> , 30(3):221-231, (1993).
	78	Brett et al., "The invasins protein of Yersinia spp. Provides co-stimulatory activity to human T cells thorough interaction with beta 1 integrins," <i>Eur. J. Immunol.</i> , 23(7):1608-1614 (1993).
	79	Cello, J, et al., "Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides," <i>J. Clin. Microbiol.</i> , 31(4):911-916 (1993).
	80	Chien et al., "Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides," <i>Proc Natl Acad Sci USA</i> , 88:9578-9582 (1991).
	81	Cohen, J., et al., "Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes," <i>Proc. Natl. Acad. Sci. USA</i> , 87(13):4922-4926 (1990).
	82	Colberre-Garapin et al., "A new dominant hybrid selective marker for higher eukaryotic cells," <i>J. Molecular Biology</i> , 150:1 (1981).
EXAMINER		DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.007CP3C1	APPLICATION NO. 10/608,541
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) 		APPLICANT Matti Sällberg	
		FILING DATE June 27, 2003	GROUP Unknown


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
83	Database Genseq 'Online! October 21, 1991, Asahi Chemical Ind. KK: "L-chain variable region of plasminogen activator antibody" XP002183673, Accession AAP61027 (published in JP11729000)
84	Database Genseq 'Online! January 8, 1993, Clonatec SA: "Hepatitis B virus HBc antigen II," XP002183674, Accession AAR25272 (published in EP494825)
85	Database Genseq 'Online! July 1, 1993, Cytel Corp: "Cytotoxic T-lymphocyte inducing peptide 802.03." XP002183675, Accession AAR33488
86	Database WPI, Section Ch., Week 199713, Derwent Publications Ltd., London, GB: Class B04, AN 1997-140911, XP002183678 & JP 09 020798 A (Asahi Kasei Kogyo KK) January 21, 1997, abstract
87	Database Patent_PRT 'Online! March 21, 2001, Eurodiagnostica AB: "Sequence 9 from Patent W)0116163" XP002183677, Accession AX 090806
88	Database Genseq 'Online! July 31, 2000, Yeda Res & Dev Co Ltd: "Murine anti-Pab-421 IDI-1 mAb heavy chain CDR based Peptide IDI-H1", XP002183676, Accession AAY70799 (published in WO0023082)
89	Doolittle et al., "The amino Acid Sequence of the alpha-Chain of Human Fibrinogen." <i>Nature</i> , 280(5722):464-468, (1979).
90	Felding-Habermann et al., "Role of β 3 Integrins in Melanoma cell Adhesion to Activated Platelets under Flow," <i>J. Biol. Chem.</i> , 271(10):5892-5900 (1996).
91	Flock, "Extracellular-Matrix-Binding Proteins as Targets for the Prevention of Staphylococcus Aureus Infections," <i>Molecular Medicine Today</i> , 5(12):532-537 (1999).
92	Ganem, "Hepadnaviridae and their replication," <i>Fields Virology</i> , Third Ed., pp. 2703-2705 (1996)
93	GenCore Sequence Alignment of Sequence ID No: 16 with the L-chain variable region of plasminogen activator antibody of JP61172900-A, Ashi Chemical Ind. KK. (04/08/86) ID NO: p. 61027
94	Grabowska et al., "Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1," <i>Journal of General Virology</i> , 80(pt.7):1789-1798 (1999)
95	Greenspan et al., <i>Nature Biotechnology</i> , 7:936-937 (1999)
96	Haseltine, "Replication and Pathogenesis of the AIDS Virus," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1(3):217-240 and 231-236, (1988).
97	Henschen et al., "Amino acid sequence of human fibrin. Preliminary note on the Completion of the β -Chain Sequence," <i>Z. Physiol. Chem.</i> , 358(12):1643-1646 (1977).
98	Holliger et al., "Diabodies: Small Bivalent and Bispecific Antibody Fragments," <i>Proc Natl Acad Sci USA</i> , 90(14):6444-6448, (1993).
99	Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in Phage Lambda," <i>Science</i> , 256:1275-1281 (1989)
100	Jin et al., "Expression, Isolation, and Characterization of the Hepatitis C Virus ATPase/RNA Helicase," <i>Archives of Biochemistry and Biophysics</i> , 323:47-53 (1995)
101	Katada et al., "A Novel Peptide Motif for Platelet Fibrinogen Receptor Recognition," <i>J. Biol. Chem.</i> , 272(12):7720-7726 (1997).
102	Kreitman et al., "Immunotoxins for targeted cancer therapy," <i>Advanced Drug Delivery Reviews</i> , 31:53-88 (1998).
103	Korba and Gerin, "Generation of a large combinatorial library of immunoglobulin repertoire in Phage Lambda," <i>Science</i> , 256:1275-1281 (1989)
104	Korba and Milman, "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Res</i> , 15(3):217-228 (1991)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.007CP3C1	APPLICATION NO. 10/608,541
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Matti Sällberg	
		FILING DATE June 27, 2003	GROUP Unknown

EXAMINER INITIALS	MARK OFFICE	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
		105 Lazdina et al., Journal of Virology, 75(14):6367-6374 (2001)
		106 Leanna & Hannink, "The reverse two-hybrid system: a genetic scheme for selection against specific protein/protein interactions," <i>Nucl. Acid Res.</i> , 24:3341-3347 (1996)
		107 Lee et al., "Predominant Etiologic Association of Hepatitis C Virus with Hepatocellular Carcinoma Compared with Hepatitis B Virus in Elderly Patients in a Hepatitis B-Endemic Area," <i>Cancer</i> , 72:2564-2567
		108 Levi et al., "A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro," <i>Proc Natl Acad Sci USA</i> , 90(10):4374-4378, (1993).
		109 Lew et al., "Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions," <i>Vaccine</i> , England, Vol. 18, No. 16, pp. 1681-1685 (2000).
		110 Lottspeich et al., "Amino acid sequence of human fibrin. Preliminary note on the Completion of the gamma-Chain Sequence," <i>Z. Physiol. Chem.</i> , 358(7):935-938 (1977)
		111 Lowman HB, "Bacteriophage display and discovery of peptide leads for drug development," <i>Annu. Rev. Biophys. Biomol. Struct.</i> , 26:401-424 (1997).
		112 Machida et al., "Antigenic sites on the arginine-rich carboxyl-terminal domain of the capsid protein of hepatitis B virus distinct from hepatitis B core or e antigen," <i>Mol. Immunol.</i> 26(4):421-431 (1989)
		113 McDevitt et al., "Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen," <i>Eur. J. Biochem.</i> , 247(1):416-424 (1997).
		114 McDevitt et al., "Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus," <i>Molecular Microbiology</i> , Vol. 16, No. 5, pp. 895-907 (1995)
		115 Milich et al., "The humoral immune response in acute and chronic hepatitis B virus infection," <i>Springer Semin. Immunopathol.</i> , 17:149-166 (1995)
		116 Milich et al., "The Nucleocapsid of Hepatitis B Virus is both a T-Cell-Independent Antigen," <i>Science</i> , 234:1398-1401 (1986)
		117 Milich et al., "Role of B cells in antigen presentation of the hepatitis B core," <i>Proc. Natl. Acad. Sci. USA</i> , 94:14648-14653 (1997)
		118 Mollick, et al., "Localization of a Site on Bacterial Superantigens that Determines T Cell Receptor β Chain Specificity," <i>J. Exp. Med.</i> , 177:283-293 (1993)
		119 Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc Natl Acad Sci USA</i> , 81(21):6851-6855 (1984).
		120 Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
		121 Ogg, et al., "Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes," <i>British Journal of Cancer</i> , 82(5):1058-1062 (2000)
		122 Owens et al., "Mapping the Collagen-Binding Site of Human Fibronectin by Expression in Escherichia Coli," <i>Embo Journal</i> , IRL Press, Eynsham, GB, Vol. 5, No. 11, pp. 2825-2830 (1986).
		123 Pei et al., "Functional Studies of a Fibrinogen Binding Protein from Staphylococcus Epidermidis," <i>Infection and Immunity</i> , 67(9):4525-4530 (1999).
		124 Prange et al., <i>Journal of Biological Chemistry</i> , 380(3):305-314 (1999)
		125 Roivanen et al., "Antigenic regions of poliovirus type 3/Sabin capsid proteins recognized by human sera in the peptide scanning technique," <i>Virology</i> , 180:99-107 (1991).
		126 R��ther and M��ller-Hill, "Easy identification of cDNA clones," <i>EMBO Journal</i> , 2(10):1791-1794 (1983).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.007CP3C1	APPLICATION NO. 10/608,541
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (SEE OTHER SHEETS IF NECESSARY)		APPLICANT Matti Sällberg	
		FILING DATE June 27, 2003	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	127	Salfeld et al., "Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus," <i>Journal of Virology</i> , 63(2):798-808 (1989)
	128	Sällberg et al., "Characterization of a linear binding site for a monoclonal antibody to hepatitis B core antigen," <i>J. Med. Virol.</i> , 33(4):248-252 (1991)
	129	Sällberg et al., "Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences," <i>Journal of General Virology</i> , 74:1335-1340 (1993)
	130	Sällberg et al., "Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant," <i>Mol. Immunol.</i> , 28(7):719-726 (1991)
	131	Sällberg et al., "Rapid 'tea-bag' peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins," <i>Immunology Letters</i> , 30:59-68 (1991)
	132	Sällberg et al., "Synthetic peptides as mini antibodies," Peptides: Chemistry and Biology , eds. Hodges, R. and J. Rivier, ESCOM, Leiden, pp. 715-718 (1993)
	133	Sällberg et al., "The Antigen/Antibody Specificity Exchanger: A New Peptide Based Tool for Re-directing Antibodies of Other Specificities to Recognize the V3 Domain of HIV-1 GP120," <i>Biochemical and Biophysical Research Communications</i> , 205:1386-1390 (1994).
	134	Sällberg, M. "Ligand/Receptor Specificity Exchangers that Redirect Antibodies to Receptors on a Pathogen," U.S. Patent Application Serial Number 09/664,025, Filed September 19, 2000.
	135	Sällberg, M. "Ligand/Receptor Specificity Exchangers that Redirect Antibodies to Receptors on a Pathogen," U.S. Patent Application Serial Number 09/664,945, Filed September 19, 2000.
	136	Sällberg, M. "Synthetic Peptides That Bind to the Hepatitis B Virus Core and E Antigens," U.S. Patent Application Serial Number 10/153,271, Filed May 21, 2002.
	137	Saragovi et al., "Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region," <i>Science</i> , 253(5021):792-795 (1991).
	138	Schodel et al., "Structure of Hepatitis B Virus Core and e-antigen," <i>The Journal of Biological Chemistry</i> , 268:1332-1337 (1993)
	139	Sequence alignment of Genseq sequence alignment of instant SEQ. ID NO.: 28 with the antihuman parathyroid hormone-related protein of JP04228089-A, Kaneka Corp., (08/18/92), ID NO.: AR27008
	140	Sequence alignment of Genseq sequence alignment of instant SEQ. ID NO.: 29 with anti-DNA antibody 7b3 heavy chain variable region of WO 96/36361-a1. University of Michigan, (08/12/97) ID NO: AAW04593
	141	Sequence alignment of Genseq sequence alignment of instant SEQ. ID NO.: 33 with anti-proenkephalin antibody PE-19 of WO 9606863, University of Dundee (10/09/96) ID NO: AAR91370
	142	Skrivvelis et al., <i>Scand. J. Immunol.</i> , 37:637-643 (1993)
	143	Steinbergs et al., <i>Proceedings of the Latvian Academy of Sciences, Section B</i> , 50(2):74-77 (1996)
	144	Takahashi et al., "Acute hepatitis in rats expressing human hepatitis B virus transgenes," <i>Proc. Natl. Acad. Sci USA</i> , 92:1470-1474 (1995)
	145	Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314:452-454 (1985).
	146	Taub, R., et al., "A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen," <i>J. Biol. Chem.</i> , 264(1):259-265 (1989).
	147	Tramontano et al., "The making of the minibody: an engineered β -protein for the display of conformationally constrained peptides," <i>J. of Molecular Recognition</i> , 7(1):9-24 (1994).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. TRIPEP.007CP3C1	APPLICATION NO. 10/608,541
	APPLICANT Matti Sällberg	
	FILING DATE June 27, 2003	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	148	Watt et al., "Amino Acid Sequence of the β Chain of Human Fibrinogen," <i>Biochemistry</i> , 18(1):68-76 (1979).
	149	Watt et al., "Amino acid sequence studies on the alpha chain of human fibrinogen overlapping sequences providing the complete sequence," <i>Biochemistry</i> , 18(24):5410-5416 (1979).
	150	Williams et al., "Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity," <i>J. Biol. Chem.</i> , 266(8):5182-5190 (1991).
	151	Williams et al., "Development of biologically active peptides based on antibody structure," <i>Proc Natl Acad Sci USA</i> , 86(14):5537-5541 (1989).
	152	Winter and Milstein, "Man-made antibodies," <i>Nature</i> , 349(6307):293-299 (1991).
	153	Wood et al., <i>Veterinary Immunology and Immunopathology</i> , 54(1-4):33-44 (1999)
	154	Zanetti, "Antigenized Antibodies," <i>Nature</i> , 355:476-477 (1992).
	155	Zhang et al., "Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleotide triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," <i>Clin. Diag. Lab. Immunol.</i> , 7(1):58-63 (2000)
	156	Zhang et al., "Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the hos-derived GOR protein," <i>Clin. Exp. Immunol.</i> , 6(33):403-409 (1994)

S:\DOCS\ESF\ESF-7051.DOC
 090503

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	